CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (a GLP-1 receptor agonist), given as one once-weekly subcutaneous injection.

How much weight loss did CagriSema show?

In the Phase 3 REDEFINE 1 trial (68 weeks, ~3,417 participants), CagriSema produced mean weight loss of about 22.7% on the efficacy estimand (versus ~2.3% placebo), with 40.4% of participants losing 25% or more of body weight. This was below Novo Nordisk's own ~25% target, which the market viewed as a disappointment.

How is CagriSema different from semaglutide alone?

CagriSema adds cagrilintide, a long-acting amylin analogue, to semaglutide. Amylin works through a satiety circuit that is mechanistically distinct from GLP-1, so the two are additive - the combination outperformed either component alone in REDEFINE 1.

Are the CagriSema components available as research compounds?

Yes - both components are established reference peptides. New-U catalogues cagrilintide and semaglutide as lyophilised reference peptides with per-batch Certificates of Analysis, research use only, not for human consumption. The fixed-dose CagriSema combination itself is a proprietary Novo Nordisk product.

Shop by goal

Popular compounds

Research resources

Certificates of Analysis

CagriSema (Cagrilintide + Semaglutide): A Research Guide to the Amylin + GLP-1 Combination

Q: Is CagriSema approved?

No. As of mid-2026 CagriSema has no marketing authorisation. Novo Nordisk has filed a New Drug Application with the U.S. FDA, but it has not been approved. The MHRA and EMA have not approved it either.

Short answer: CagriSema is two molecules in one weekly injection — cagrilintide 2.4 mg, a long-acting amylin analogue , plus semaglutide 2.4 mg, the GLP-1 agonist behind Wegovy. Novo Nordisk pairs them because amylin and GLP-1 suppress appetite through different circuits, so the effects stack. Phase 3 REDEFINE 1 reported ~22.7% mean weight loss at 68 weeks — impressive, but below Novo’s own ~25% target. An FDA filing is in; no marketing authorisation exists anywhere as of mid-2026. Both components are catalogued by New-U as research references. Part of our next obesity-research wave overview.

Plain-English summary. CagriSema (the fixed-dose product) is unapproved and investigational. The components , cagrilintide and semaglutide, are well-characterised research-reference peptides New-U catalogues for laboratory use — research use only, not for human consumption. This page is general information, not legal or medical advice; do not use unapproved compounds on people.

What CagriSema actually is

CagriSema is not a new molecule — it is a fixed-dose combination of two existing ones in a single weekly subcutaneous shot:

Cagrilintide 2.4 mg — a long-acting analogue of amylin , the satiety hormone co-secreted with insulin from pancreatic beta cells.

Semaglutide 2.4 mg — the 31-amino-acid GLP-1 receptor agonist already approved as Wegovy and Ozempic. See our semaglutide research guide.

The logic is mechanistic complementarity, covered next.

Why amylin + GLP-1 is additive

GLP-1 and amylin both reduce appetite, but they do it through distinct circuits , which is exactly why combining them works:

GLP-1 (semaglutide) — slows gastric emptying, acts on hypothalamic and hindbrain appetite centres, and improves glucose-dependent insulin secretion.

Amylin (cagrilintide) — signals satiety through amylin receptors and, importantly, appears to restore leptin sensitivity , so the “I’m full” signal lands harder. This is a different lever from GLP-1.

Because the two pathways are largely non-overlapping, REDEFINE 1 showed the combination beating either component on its own. For the amylin mechanism in isolation, see our guide to the pure amylin analogue petrelintide.

The REDEFINE Phase 3 evidence

REDEFINE 1 was a 68-week trial in ~3,417 adults with obesity or overweight plus at least one weight-related comorbidity (mean baseline weight 106.9 kg). Headline results:

Metric CagriSema Placebo Mean weight loss (efficacy estimand) ~−22.7% ~−2.3% Mean weight loss (treatment-policy estimand) ~−20.4% ~−3.0% Participants reaching ≥25% weight loss 40.4% 0.9% Participants reaching ≥5% weight loss 91.9% 31.5%

For context, in the same comparison cagrilintide alone and semaglutide alone produced far fewer ≥25% responders (~6% and ~16% respectively), illustrating the additive effect. In the diabetes companion trial REDEFINE 2, CagriSema delivered a superior HbA1c reduction of ~1.91%.

The 25% story. Novo Nordisk had guided the market toward roughly 25% mean weight loss. Landing at ~22.7% was a clinically strong result that nonetheless missed expectations — a reminder that in this field the bar is now set by the previous best, not by placebo. Novo subsequently filed for FDA approval.

How CagriSema compares

Compound Mechanism Best documented mean weight loss Status CagriSema Amylin + GLP-1 ~22.7% / 68 wks NDA filed Semaglutide GLP-1 ~14.9% / 68 wks (STEP-1) Approved Tirzepatide GLP-1 + GIP ~20.9% / 72 wks (SURMOUNT-1) Approved Retatrutide GLP-1 + GIP + glucagon ~24.2% / 48 wks (Phase 2) Phase 3, no approval

CagriSema components as research compounds

Unusually for this pipeline, both CagriSema components are established, verifiable research-reference peptides that New-U catalogues:

Cagrilintide — the long-acting amylin analogue, the same molecule studied in the REDEFINE programme.

Semaglutide — the GLP-1 single agonist.

Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity by Janoshik and Freedom Diagnostics, with a per-batch Certificate of Analysis — research use only, not for human consumption . The fixed-dose CagriSema co-formulation itself is a proprietary Novo Nordisk product and is not a research reagent.

How to verify the components’ purity

HPLC purity >99% by reversed-phase chromatography, on each component.

Mass-spec identity match to the calculated mass of the cagrilintide and semaglutide sequences.

Named third-party lab on the CoA, with a batch number tied to the vial.

Full walkthrough: How to Read a Certificate of Analysis.

Frequently Asked Questions

What is CagriSema? Novo Nordisk’s investigational once-weekly combination of cagrilintide 2.4 mg (amylin analogue) and semaglutide 2.4 mg (GLP-1 agonist).

Is CagriSema approved? No. An FDA filing is in progress, but as of mid-2026 there is no marketing authorisation anywhere.

How much weight loss? ~22.7% mean over 68 weeks in REDEFINE 1 — strong, but below Novo’s ~25% target.

Why combine amylin and GLP-1? They suppress appetite through different circuits, so the effect is additive — the combination beat either component alone.

Are the components available for research? Yes — New-U catalogues cagrilintide and semaglutide as reference peptides, research use only.

Primary sources & further reading

Novo Nordisk — CagriSema REDEFINE 1 results

Novo Nordisk — REDEFINE 2 (type-2 diabetes) HbA1c result

U.S. National Library of Medicine — PubMed: cagrilintide / semaglutide

ClinicalTrials.gov — REDEFINE programme

U.S. FDA — FDA (CagriSema not approved as of publication)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Cagrilintide & Semaglutide

New-U Research Compounds catalogues both CagriSema components — cagrilintide and semaglutide — as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy Cagrilintide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

CagriSema (Cagrilintide + Semaglutide): A Research Guide to the Amylin + GLP-1 Combination

What CagriSema actually is

Why amylin + GLP-1 is additive

The REDEFINE Phase 3 evidence

How CagriSema compares

CagriSema components as research compounds

How to verify the components’ purity

Frequently Asked Questions

Related Reading

Primary sources & further reading

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Cagrilintide & Semaglutide

Buy Cagrilintide from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide